Mirum Pharmaceuticals, Inc.(MIRM)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

MIRM Mirum Pharmaceuticals, Inc.

交易中 03-23 10:18:19 EDT

88.63

+0.12

+0.14%

最高91.24	最低87.94	成交量15.81万
今开88.98	昨收88.51	日振幅3.73%
总市值53.48亿	流通市值35.44亿	总股本6,034万
成交额1,419万	换手率0.40%	流通股本3,999万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"MIRM","market":"US","secType":"STK","nameCN":"Mirum Pharmaceuticals, Inc.","latestPrice":88.63,"timestamp":1774275494928,"preClose":88.51,"halted":0,"volume":158079,"delay":0,"changeRate":0.0013557790080215833,"floatShares":39985740,"shares":60341617,"eps":-0.47,"marketStatus":"交易中","change":0.12,"latestTime":"03-23 10:18:19 EDT","open":88.98,"high":91.24,"low":87.94,"amount":14191986.42699,"amplitude":0.037284,"askPrice":89.25,"askSize":110,"bidPrice":88.63,"bidSize":240,"shortable":3,"etf":0,"ttmEps":-0.47,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1774296000000},"marketStatusCode":2,"adr":0,"listingDate":1563422400000,"exchange":"NASDAQ","adjPreClose":88.51,"preHourTrading":{"tag":"盘前","latestPrice":88.79,"preClose":88.51,"latestTime":"09:29 EDT","volume":2593,"amount":231410.51138799998,"timestamp":1774272599999,"change":0.28,"changeRate":0.003163,"amplitude":0.033669},"postHourTrading":{"tag":"盘后","latestPrice":88.51,"preClose":88.51,"latestTime":"19:16 EDT","volume":481179,"amount":42589131.7667,"timestamp":1774048580022,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.052283,"impliedVol":0.7895,"impliedVolPercentile":0.992},"requestUrl":"/m/hq/s/MIRM","defaultTab":"news","newsList":[{"id":"1121811592","title":"Mirum制药完成Livmarli®治疗罕见胆汁淤积性肝病三期扩展研究患者招募","url":"https://stock-news.laohu8.com/highlight/detail?id=1121811592","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1121811592?lang=zh_cn&edition=full","pubTime":"2026-03-16 20:40","pubTimestamp":1773664821,"startTime":"0","endTime":"0","summary":"Mirum Pharmaceuticals, Inc.宣布已完成Livmarli®（maralixibat）针对其他罕见胆汁淤积性肝病的三期扩展研究（EXPAND）患者招募工作。\n该研究的顶线数据预计将于2026年第四季度公布。这项进展标志着Mirum在拓展罕见肝病治疗领域迈出关键一步，为患者带来新的希望。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MIRM"],"gpt_icon":0},{"id":"1124176149","title":"Mirum制药公司：Azure-1与Azure-4预计将于2027年在美国提交BLA申请并上市","url":"https://stock-news.laohu8.com/highlight/detail?id=1124176149","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1124176149?lang=zh_cn&edition=full","pubTime":"2026-03-05 21:04","pubTimestamp":1772715899,"startTime":"0","endTime":"0","summary":"Mirum Pharmaceuticals, Inc. 旗下药物Azure-1和Azure-4有望在2027年向美国监管机构提交生物制剂许可申请（BLA），并计划同期实现商业化上市。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MIRM"],"gpt_icon":0},{"id":"1176149465","title":"Mirum Pharmaceuticals公布Brelovitug治疗慢性丁型肝炎病毒Azure临床项目最新进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1176149465","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1176149465?lang=zh_cn&edition=full","pubTime":"2026-03-05 21:02","pubTimestamp":1772715730,"startTime":"0","endTime":"0","summary":"Mirum Pharmaceuticals, Inc.近日针对其候选药物Brelovitug在慢性丁型肝炎病毒感染治疗中的Azure临床研究项目，发布了最新动态更新。此次更新涵盖了该临床试验项目的关键进展与后续规划。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIRM","BK4139"],"gpt_icon":0},{"id":"1177135125","title":"异动解读 | Evercore上调目标价并看好药物潜力，Mirum Pharmaceuticals盘中大涨5.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=1177135125","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177135125?lang=zh_cn&edition=full","pubTime":"2026-03-05 03:09","pubTimestamp":1772651362,"startTime":"0","endTime":"0","summary":"Mirum Pharmaceuticals, Inc.  今日盘中股价大幅上涨5.07%，引起了市场的广泛关注。消息面上，知名投行Evercore ISI将Mirum Pharmaceuticals的目标价从101美元大幅上调至126美元，并重申了“跑赢大盘”的评级。具体来看，Mirum预计将在2026年第二季度获得实验性肝病药物volixibat的中期数据以及D型肝炎候选药物brelovitug的中晚期数据。券商预计，用于治疗原发性硬化性胆管炎的volixibat在全球的未调整峰值销售额可达12亿美元，这进一步增强了市场对公司未来增长潜力的信心。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["MIRM"],"gpt_icon":0},{"id":"1101130484","title":"Mirum制药公司提交SEC文件：股东拟发售最高896万股普通股","url":"https://stock-news.laohu8.com/highlight/detail?id=1101130484","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1101130484?lang=zh_cn&edition=full","pubTime":"2026-02-26 06:20","pubTimestamp":1772058025,"startTime":"0","endTime":"0","summary":"根据最新提交给美国证券交易委员会（SEC）的文件显示，Mirum Pharmaceuticals, Inc.已正式登记由售股股东发起的普通股公开发行计划。此次发售规模最高可达896万股，所有股份均由现有股东提供，公司本身不会从此次发售中获得任何收益。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIRM","BK4139"],"gpt_icon":0},{"id":"2610100930","title":"Mirum Pharmaceuticals, Inc.跌0.54% 股价跌破100美元大关","url":"https://stock-news.laohu8.com/highlight/detail?id=2610100930","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610100930?lang=zh_cn&edition=full","pubTime":"2026-02-10 22:32","pubTimestamp":1770733977,"startTime":"0","endTime":"0","summary":"北京时间2026年02月10日22时32分，Mirum Pharmaceuticals, Inc.股票出现波动，股价快速跳水0.54%。Mirum Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为0.02%。其相关个股中，Quince Therapeutics, Inc.、Abpro Holdings, Inc、Evommune, Inc.涨幅较大，Abpro Holdings, Inc、Phio Pharmaceuticals Corp.、Quince Therapeutics, Inc.较为活跃，换手率分别为991.87%、627.18%、448.48%，振幅较大的相关个股有Quince Therapeutics, Inc.、Abpro Holdings, Inc、Evommune, Inc.，振幅分别为52.69%、15.79%、12.95%。Mirum Pharmaceuticals, Inc.公司简介：Mirum Pharmaceuticals Inc 是一家生物制药公司， 专注于识别、收购、开发和商业化用于使人衰弱的罕见疾病和孤儿疾病的新疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260210223258a4940720&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260210223258a4940720&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["MIRM","BK4139"],"gpt_icon":0},{"id":"1115897314","title":"Mirum Pharmaceuticals宣布加拿大卫生部批准Livmarli®用于治疗进行性家族性肝内胆汁淤积症（PFIC）患者的胆汁淤积性瘙痒","url":"https://stock-news.laohu8.com/highlight/detail?id=1115897314","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1115897314?lang=zh_cn&edition=full","pubTime":"2026-02-05 21:00","pubTimestamp":1770296417,"startTime":"0","endTime":"0","summary":"Mirum Pharmaceuticals, Inc. 近日宣布，加拿大卫生部已正式批准其药物Livmarli®用于治疗进行性家族性肝内胆汁淤积症（PFIC）患者的胆汁淤积性瘙痒。这一授权标志着该药物在加拿大市场的准入，为患有此种罕见肝病的患者提供了新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIRM","BK4139"],"gpt_icon":0},{"id":"1156667431","title":"Mirum制药完成收购Bluejay Therapeutics 强化罕见病领域全球领导地位","url":"https://stock-news.laohu8.com/highlight/detail?id=1156667431","media":"美股速递","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1156667431?lang=zh_cn&edition=full","pubTime":"2026-01-26 21:01","pubTimestamp":1769432497,"startTime":"0","endTime":"0","summary":"Mirum Pharmaceuticals, Inc.近日宣布已完成对Bluejay Therapeutics公司的全面收购。这一战略举措显著拓展了Mirum在罕见病治疗领域的全球布局，进一步巩固了其行业领先地位。通过本次收购，Mirum获得了Bluejay Therapeutics在罕见肝病领域的创新研发管线及专业技术。这将为Mirum现有产品组合注入新的活力，增强其解决复杂罕见疾病的能力。此次交易不仅拓展了Mirum的全球业务版图，更彰显了其长期致力于罕见病治疗领域的坚定承诺。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MIRM"],"gpt_icon":0},{"id":"2603688965","title":"Mirum Pharmaceuticals, Inc.盘中异动 股价大跌5.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603688965","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603688965?lang=zh_cn&edition=full","pubTime":"2026-01-12 22:37","pubTimestamp":1768228674,"startTime":"0","endTime":"0","summary":"北京时间2026年01月12日22时37分，Mirum Pharmaceuticals, Inc.股票出现异动，股价急速跳水5.28%。Mirum Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为1.44%。Mirum Pharmaceuticals, Inc.公司简介：Mirum Pharmaceuticals Inc 是一家生物制药公司， 专注于识别、收购、开发和商业化用于使人衰弱的罕见疾病和孤儿疾病的新疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260112223754a7120935&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260112223754a7120935&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["MIRM","BK4139"],"gpt_icon":0},{"id":"1185803639","title":"Mirum制药公司2025年初步净产品销售额约5.2亿美元 超预期指引上限","url":"https://stock-news.laohu8.com/highlight/detail?id=1185803639","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1185803639?lang=zh_cn&edition=full","pubTime":"2026-01-12 21:33","pubTimestamp":1768224780,"startTime":"0","endTime":"0","summary":"Mirum Pharmaceuticals, Inc. 近日公布的2025年初步业绩数据显示，其净产品销售额达到约5.2亿美元，这一数字显著超越了公司此前设定的业绩指引上限。\n这一亮眼成绩凸显了公司核心产品的市场竞争力与商业化进展。销售额的超预期表现，不仅反映了患者需求的持续增长，也印证了公司销售策略的有效执行。在医药行业面临多重挑战的背景下，Mirum能够实现如此强劲的销售增长，为其未来的发展奠定了坚实的基础。\n市场分析人士认为，这一积极的初步数据可能会增强投资者信心，并对公司未来的股价表现产生积极影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MIRM"],"gpt_icon":0},{"id":"1116304908","title":"Mirum制药公司：伏利昔巴特治疗原发性硬化性胆管炎Vistas研究顶线数据预计2026年第二季度公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1116304908","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1116304908?lang=zh_cn&edition=full","pubTime":"2026-01-12 21:32","pubTimestamp":1768224761,"startTime":"0","endTime":"0","summary":"Mirum Pharmaceuticals, Inc.宣布，其针对原发性硬化性胆管炎（PSC）开发的伏利昔巴特（volixibat）Vistas研究，预计将于2026年第二季度获得顶线数据。该研究旨在评估伏利昔巴特治疗这一慢性胆汁淤积性肝病的疗效与安全性。\n此次数据公布将成为评估该疗法潜力的关键节点，备受市场关注。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MIRM"],"gpt_icon":0},{"id":"1137824651","title":"Mirum Pharma首席执行官表示，Brelovitug的加入将使其罕见疾病组合的收入潜力超过40亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1137824651","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1137824651?lang=zh_cn&edition=full","pubTime":"2025-12-08 21:43","pubTimestamp":1765201436,"startTime":"0","endTime":"0","summary":"Mirum Pharma首席执行官表示，Brelovitug的加入将使其罕见疾病组合的收入潜力超过40亿美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIRM","BK4139"],"gpt_icon":0},{"id":"1114154154","title":"Mirum Pharmaceuticals拟以2.5亿美元现金、3.7亿美元公司普通股以及最多2亿美元的销售里程碑付款收购Bluejay","url":"https://stock-news.laohu8.com/highlight/detail?id=1114154154","media":"美股速递","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1114154154?lang=zh_cn&edition=full","pubTime":"2025-12-08 21:06","pubTimestamp":1765199171,"startTime":"0","endTime":"0","summary":"Mirum Pharmaceuticals拟以2.5亿美元现金、3.7亿美元公司普通股以及最多2亿美元的销售里程碑付款收购Bluejay。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MIRM"],"gpt_icon":0},{"id":"1168670915","title":"Mirum Pharmaceuticals：与医疗投资者联络组达成私募协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1168670915","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1168670915?lang=zh_cn&edition=full","pubTime":"2025-12-08 21:03","pubTimestamp":1765199025,"startTime":"0","endTime":"0","summary":"Mirum Pharmaceuticals：与医疗投资者联络组达成私募协议","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MIRM"],"gpt_icon":0},{"id":"1133302222","title":"Mirum Pharmaceuticals达成收购Bluejay Therapeutics的最终协议，扩展在罕见疾病领域的全球领导地位","url":"https://stock-news.laohu8.com/highlight/detail?id=1133302222","media":"美股速递","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1133302222?lang=zh_cn&edition=full","pubTime":"2025-12-08 21:03","pubTimestamp":1765198995,"startTime":"0","endTime":"0","summary":"Mirum Pharmaceuticals达成收购Bluejay Therapeutics的最终协议，扩展在罕见疾病领域的全球领导地位","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MIRM"],"gpt_icon":0},{"id":"1194128623","title":"Mirum Pharmaceuticals：预计私人融资将与收购同时完成，并为公司带来约2亿美元的总收益","url":"https://stock-news.laohu8.com/highlight/detail?id=1194128623","media":"美股速递","labels":["shareholding","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1194128623?lang=zh_cn&edition=full","pubTime":"2025-12-08 21:01","pubTimestamp":1765198897,"startTime":"0","endTime":"0","summary":"Mirum Pharmaceuticals：预计私人融资将与收购同时完成，并为公司带来约2亿美元的总收益","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MIRM"],"gpt_icon":0},{"id":"1157964241","title":"Mirum Pharmaceuticals：Azure三期项目正在招募患者，预计在2026年下半年获得主要数据，BLA申请及计划于2027年上市","url":"https://stock-news.laohu8.com/highlight/detail?id=1157964241","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1157964241?lang=zh_cn&edition=full","pubTime":"2025-12-08 21:01","pubTimestamp":1765198895,"startTime":"0","endTime":"0","summary":"Mirum Pharmaceuticals：Azure三期项目正在招募患者，预计在2026年下半年获得主要数据，BLA申请及计划于2027年上市","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MIRM"],"gpt_icon":0},{"id":"1145122409","title":"Mirum Pharmaceuticals宣布在Bloom第二阶段临床研究中招募首位患者，评估Mrm-3379在脆性X综合症中的应用","url":"https://stock-news.laohu8.com/highlight/detail?id=1145122409","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1145122409?lang=zh_cn&edition=full","pubTime":"2025-12-01 21:11","pubTimestamp":1764594695,"startTime":"0","endTime":"0","summary":"Mirum Pharmaceuticals宣布在Bloom第二阶段临床研究中招募首位患者，评估Mrm-3379在脆性X综合症中的应用","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIRM","BK4139"],"gpt_icon":0},{"id":"2516480605","title":"Mirum Pharmaceuticals, Inc.2024财年实现净利润-87.94百万美元，同比增加46.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516480605","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516480605?lang=zh_cn&edition=full","pubTime":"2025-03-03 00:01","pubTimestamp":1740931269,"startTime":"0","endTime":"0","summary":"3月3日，Mirum Pharmaceuticals, Inc.公布财报，公告显示公司2024财年净利润为-87.94百万美元，同比增加46.05%；其中营业收入为3.37亿美元，同比增加81.18%，每股基本收益为-1.85美元。从资产负债表来看，Mirum Pharmaceuticals, Inc.总负债4.45亿美元，其中短期债务1.71百万美元，资产负债比为1.51，流动比率为3.10。机构评级：截至2025年3月3日，当前有9家机构对Mirum Pharmaceuticals, Inc.目标价做出预测，其中目标均价为66.11美元，其中最低目标价为55.00美元，最高目标价为74.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303000148abe4acd0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303000148abe4acd0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["MIRM"],"gpt_icon":0},{"id":"2514651385","title":"Mirum Pharmaceuticals, Inc.盘中异动 早盘大幅跳水7.68%报46.64美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514651385","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514651385?lang=zh_cn&edition=full","pubTime":"2025-02-27 22:32","pubTimestamp":1740666722,"startTime":"0","endTime":"0","summary":"北京时间2025年02月27日22时32分，Mirum Pharmaceuticals, Inc.股票出现波动，股价急速下跌7.68%。Mirum Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.31%。Mirum Pharmaceuticals, Inc.公司简介：Mirum Pharmaceuticals Inc 是一家生物制药公司，专注于识别、收购、开发和商业化用于使人衰弱的罕见疾病和孤儿疾病的新疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502272232029632b0e4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502272232029632b0e4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["MIRM","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.mirumpharma.com","stockEarnings":[{"period":"1week","weight":-0.0237},{"period":"1month","weight":-0.1578},{"period":"3month","weight":0.1385},{"period":"6month","weight":0.19},{"period":"1year","weight":0.849},{"period":"ytd","weight":0.1205}],"compareEarnings":[{"period":"1week","weight":-0.0207},{"period":"1month","weight":-0.055},{"period":"3month","weight":-0.047},{"period":"6month","weight":-0.0228},{"period":"1year","weight":0.1469},{"period":"ytd","weight":-0.0489}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Mirum Pharmaceuticals, Inc.于2018年5月2日在特拉华州注册成立。该公司是一家生物制药公司，专注于识别、收购、开发和商业化用于使人衰弱的罕见和孤儿疾病的新疗法。","yearOnYearQuotes":[{"month":1,"riseRate":0.714286,"avgChangeRate":0.06611},{"month":2,"riseRate":0.714286,"avgChangeRate":0.037723},{"month":3,"riseRate":0.285714,"avgChangeRate":-0.049034},{"month":4,"riseRate":0.5,"avgChangeRate":0.059141},{"month":5,"riseRate":0.166667,"avgChangeRate":-0.035958},{"month":6,"riseRate":0.666667,"avgChangeRate":0.097654},{"month":7,"riseRate":0.666667,"avgChangeRate":0.076249},{"month":8,"riseRate":0.714286,"avgChangeRate":0.107618},{"month":9,"riseRate":0.285714,"avgChangeRate":-0.04362},{"month":10,"riseRate":0.142857,"avgChangeRate":-0.10761},{"month":11,"riseRate":0.714286,"avgChangeRate":0.084664},{"month":12,"riseRate":0.571429,"avgChangeRate":0.315468}],"exchange":"NASDAQ","name":"Mirum Pharmaceuticals, Inc.","nameEN":"Mirum Pharmaceuticals, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.37.0","shortVersion":"4.37.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Mirum Pharmaceuticals, Inc.(MIRM)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Mirum Pharmaceuticals, Inc.(MIRM)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Mirum Pharmaceuticals, Inc.,MIRM,Mirum Pharmaceuticals, Inc.股票,Mirum Pharmaceuticals, Inc.股票老虎,Mirum Pharmaceuticals, Inc.股票老虎国际,Mirum Pharmaceuticals, Inc.行情,Mirum Pharmaceuticals, Inc.股票行情,Mirum Pharmaceuticals, Inc.股价,Mirum Pharmaceuticals, Inc.股市,Mirum Pharmaceuticals, Inc.股票价格,Mirum Pharmaceuticals, Inc.股票交易,Mirum Pharmaceuticals, Inc.股票购买,Mirum Pharmaceuticals, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Mirum Pharmaceuticals, Inc.(MIRM)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Mirum Pharmaceuticals, Inc.(MIRM)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}